posted on 2018-12-06, 11:39authored byNiloofar Ajdari, Cian Vyas, Stephanie L. Bogan, Bashir A. Lwaleed, Brian Cousins
In this study, we investigated gold nanoparticle (AuNP) interactions in blood using thromboelastography as a rapid screening tool to
monitor their influence on blood coagulation. 1.2 nM colloidal AuNPs ranging from 12 to 85 nm have no effect in the blood, however, 5 nM
AuNPs demonstrate pro-thrombogenic concentration dependent effects with a reduction in clot formation. Size effects exhibit a non-linear
trend with 45 and 85 nm particles resulting in a faster pro-thrombotic response. Clot strength decreased with AuNP size with the greatest
reduction with 28 nm particles. We assessed AuNP interactions in the blood focusing on their biological activity. AuNP-RGD possessed procoagulant
activities, while PEG-thiol, human fibrinogen and clopidogrel prevented blood clot formation and influenced platelet activity, and
were more efficient when bound to nanocarriers than unbound ligands. Such tests could fill the knowledge gaps in thrombogenicity of NPs
between in vitro test methods and predict in vivo haemocompatibility.
Funding
The authors would
like to acknowledge the financial support of the EPSRC CASE Award (EP/
L504889/1), and Healthcare Impact Partnership (EP/L024713/1).
History
School
Science
Department
Chemistry
Published in
Nanomedicine: Nanotechnology, Biology and Medicine
Volume
13
Issue
4
Pages
1531 - 1542
Citation
AJDARI, N. ... et al., 2017. Gold nanoparticle interactions in human blood: a model evaluation. Nanomedicine: Nanotechnology, Biology and Medicine, 13(4), pp. 1531-1542.
This work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Full details of this licence are available at: http://creativecommons.org/licenses/ by/4.0/
Acceptance date
2017-01-31
Publication date
2017-02-24
Notes
This is an Open Access Article. It is published by Elsevier under the Creative Commons Attribution 4.0 Unported Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/